https://www.live-feeds.com/feed/bristol-myers-claims-phase-2-success-for-gprc5d-directed-car-tContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/bristol-myers-claims-phase-2-success-for-gprc5d-directed-car-thttps://www.live-feeds.com/feed/bristol-myers-claims-phase-2-success-for-gprc5d-directed-car-t#u63727Thu, 10 Sep 2026 08:20:33 +0000Bristol Myers Squibb announced that its mid-stage trial for a GPRC5D-directed CAR-T cell therapy has successfully hit its primary endpoint. The next-generation treatment, known as arlo-cel, met its overall response rate endpoint in patients with quadruple-class exposed multiple myeloma who were previously treated with BCMA therapies. This clinical trial progress marks a potential expansion milestone for the company's blood cancer portfolio. Industry analysts are evaluating how this successful mid-stage data will impact portfolio growth and future regulatory submissions for the pharmaceuti